# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ray Charles (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML009-SYN-TD
- Date: 1996-06-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Fenwick, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review of recovery, accessibility, and fall prevention. **S**

## History of present illness

Mr. Charles returns three months after his first visit. He has stayed well while touring. He keeps one naloxone spray at home and one in his travel bag, and the people he travels with have been shown how to use it. He has had no opioid or other drug use and no cravings, including on long tours and in hotel rooms, which he names as the times he is most careful. His eyes have been comfortable. He has had no falls; in hotels he is shown around each new room on arrival and keeps his belongings in fixed places. He has started working on a plan for any future pain with Dr. Fenwick. **S**

| Element | Detail |
|---|---|
| Recovery | No use and no cravings; aware of travel as a time to be careful |
| Naloxone | At home and in his travel bag; travel staff shown how to use it |
| Eyes | Comfortable |
| Falls | None; spoken orientation to each new hotel room |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No eye pain, redness, or discharge |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of suicide or self-harm |
| Musculoskeletal | Negative | No falls or pain |

3 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 79.8 kg; BMI 25.2 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert and engaged; each step of the examination described before it was done |
| Eyes | No light perception; lids and ocular surfaces quiet |
| Gait | Steady, walking independently after a spoken orientation to the room |
| Psychiatric | Euthymic; no signs of intoxication or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder, in sustained remission** (F11.21). Sustained remission continues. Naloxone is in place at home and when traveling, and his travel staff know how to use it. **S**
   - Draft the written plan for any future pain together, to be finished at the six-month visit: non-opioid treatment first, and if an opioid is ever needed after surgery or an injury, the smallest supply for the shortest time, one prescriber, a support person told, and a follow-up visit within a week.
2. **Blindness of both eyes since childhood** (H54.0X55). Eyes comfortable and quiet. **S**
   - Yearly ophthalmology review; same-day care for eye pain or redness.
3. **Fall prevention**. No falls; his routine of a spoken orientation to each new room works well. **S**
   - Continue the same routine.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Eye comfort and ocular surface check: pain, redness, discharge | Every visit | Completed today | No pain, redness, or discharge |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; for blind eyes, only if pain or redness | Not indicated | Painless blind eyes, as advised by ophthalmology |
| Examination | Comprehensive eye examination | Yearly for blind eyes, or with symptoms | Up to date | Ophthalmology examination two months ago |
| Survey | Depression screen (PHQ-9) | At intake, at six months, and yearly | Up to date | PHQ-9 2 three months ago; mood good; next at six months |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline still saved in his phone |
| Self-management | Recovery check: any return to use, cravings, triggers, and supports | Every visit | Completed today | No return to use and no cravings; touring and hotel stays named as times to be careful, with a plan to call a friend if cravings come |
| Medication safety | Naloxone at home and when traveling | At intake; check expiry at each visit | Completed today | In date, at home and in his travel bag; travel staff shown how to use it |
| Survey | Drug-use screen (DAST-10) | Yearly | Up to date | DAST-10 0 three months ago |
| Survey | Alcohol screen (AUDIT-C) | Yearly | Up to date | AUDIT-C 2 three months ago |
| Laboratory | Hepatitis C, hepatitis B, and HIV testing | At entry to care for a person with a substance use disorder | Due | Planned for the annual wellness visit, as recorded at the four-week visit |
| Self-management | Written plan for any future acute pain or surgery | Before any planned procedure, and once in remission | Due | Drafted today; to be finished at the six-month visit |
| Self-management | Accessible documents and communication | Every visit | Completed today | Visit summaries continue as accessible electronic documents |
| Medication safety | Medicine labeling in braille or audio | With every new prescription | Up to date | No new prescriptions |
| Examination | CDC STEADI fall-risk screen | Every visit from age 65 | Completed today | No falls; steady gait |
| Self-management | Advance care planning | Yearly from age 65 | Due | At the annual wellness visit |

## Goal progress

- Visit summaries, results, and medicine information delivered in an accessible electronic format, and medicine labels in braille or audio, by the four-week visit. Outcome by 1996-03-31: Visit summaries sent as accessible documents; the pharmacy provides audio labels and a braille label on the naloxone. **S**
- Naloxone at home and in his travel bag, with a tactile label, and the people he travels with shown how to use it, by the three-month visit. Outcome by 1996-06-02: Naloxone in both places; travel staff shown how to use it. **S**
- Stay in sustained remission, with no return to opioid use, through six months. In progress; target 1996-09-01. **S**
- No falls through six months. In progress; target 1996-09-01. **S**
- A written plan for any future acute pain or surgery that uses non-opioid treatment first and builds in safeguards if an opioid is ever needed, by the six-month visit. In progress; target 1996-09-01. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Primary Open-Angle Glaucoma Preferred Practice Pattern (2025), American Academy of Ophthalmology
- Vision Rehabilitation Preferred Practice Pattern (2023), American Academy of Ophthalmology (Ophthalmology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Six-month review with the PHQ-9 and the finished pain plan. **S**
- Next scheduled visit 1996-09-01: six-month review with depression screening and a plan for any future pain. **S**
